NCT05729243

Cytisine for Smoking Cessation

Cytisine: Testing Its Potential as a Therapeutic Strategy for Smoking Cessation Among People With Concurrent Alcohol Use Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Centre for Addiction and Mental Health · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of cytisine as a smoking cessation treatment in individuals with concurrent alcohol use disorder.

Conditions

• Tobacco Use Disorder
• Alcohol Use Disorder
• Smoking Cessation

Interventions

Type	Name	Description
DRUG	Cytisine	Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
OTHER	Placebo	A placebo identical in appearance to cytisine will be used

Timeline

• Start date: 2023-02-08
• Primary completion: 2025-12-12
• Completion: 2025-12-12
• First posted: 2023-02-15
• Last updated: 2026-02-27

Locations

1 site across 1 country: Canada